Viewing Study NCT07145892


Ignite Creation Date: 2025-12-24 @ 3:17 PM
Ignite Modification Date: 2025-12-24 @ 3:17 PM
Study NCT ID: NCT07145892
Status: COMPLETED
Last Update Posted: 2025-08-28
First Post: 2025-08-21
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Three-dimensional Digital Breast Tomosynthesis Versus Digital Mammography
Sponsor: The General Authority for Teaching Hospitals and Institutes
Organization:

Study Overview

Official Title: Three-dimensional Digital Breast Tomosynthesis Versus Digital Mammography: Which Get the Supremacy in Diagnosis of Benign Breast Lesions in Asymptomatic Females
Status: COMPLETED
Status Verified Date: 2025-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study aimed to compare the supremacy of (3D) tomosynthesis versus (2D) digital mammography in the diagnosis of benign breast lesions in asymptomatic females.
Detailed Description: Most of the breast lesions are benign, but much concern is given to malignant lesions because breast cancer is the most common malignancy in women.

Mammography is the only study for screening in asymptomatic patients, and it is the initial imaging study in the diagnosis of symptomatic patients, with a sensitivity for suspicious lesions of 86% and a specificity of 57%.

In recent years, a significant effort has been expended to develop new approaches to breast imaging, one of which is the use of digital breast tomosynthesis (DBT), which is a pseudo three-dimensional digital mammography system that produces a series of thin-section reconstructed images from low-dose X-ray projections at multiple angles.

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: